Individualized neuro-regenerative protocols in Istanbul
Stem cell therapy for spinal cord injury in Istanbul
Led by Uzm. Dr. Cihan Bolat, our medical team evaluates your spinal MRI scans, neurological level, and medical history to design a personalized Wharton's jelly MSC and exosome protocol supporting the spinal microenvironment and spared neural pathways.
Understanding spinal cord injury and our regenerative protocol
A spinal cord injury (SCI) causes damage in two distinct phases: the initial mechanical impact that compresses or contuses spinal nerve tracts, followed by a prolonged secondary biological cascade of neuroinflammation, ischemia, demyelination, and dense glial scar formation. Even when anatomically spared nerve fibers remain across the lesion zone, chronic microglial activation and loss of oligodendrocyte myelin insulation often prevent those surviving tracts from conducting motor, sensory, and autonomic signals effectively.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are utilized to target this secondary spinal microenvironment and help surviving neural tissue recover function. Inside the spinal canal and systemic circulation, WJ-MSCs release potent anti-inflammatory cytokines that calm destructive M1 microglia and infiltrating macrophages, shifting them toward reparative M2 phenotypes that soften inhibitory scar signaling. At the same time, WJ-MSCs and their nanoscale exosomes deliver neurotrophic growth factors — including BDNF, GDNF, NGF, HGF, and pro-angiogenic VEGF — along with regenerative microRNAs that nourish surviving neurons, support oligodendrocyte precursor cells in remyelinating spared axons, stimulate microvascular blood supply, and promote synaptic plasticity.
At our clinic in Istanbul, led by Uzm. Dr. Cihan Bolat, our medical team evaluates your spinal MRI scans, surgical stabilization reports, injury level, and AIS grade to design an individualized non-surgical protocol. By combining intrathecal WJ-MSC delivery directly into the cerebrospinal fluid with intravenous WJ-MSCs, intravenous exosomes, and intranasal exosomes alongside your ongoing physical rehabilitation, our protocols aim to support motor and trunk control, sensory awareness, spasticity comfort, and greater daily functional independence.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
What happens inside the spinal cord — and how WJ-MSCs and exosomes support repair
Beyond the initial trauma, four biological processes unfold within the spinal cord microenvironment. Our regenerative protocols are designed to target each of these pathways to help protect and repair surviving neural structures.
Therapeutic objectives of our protocol
Once your spine is surgically and medically stabilized, our regenerative protocol aims to support the biological microenvironment of the spinal cord while you continue physical rehabilitation and specialist care with your home physicians.
Modulating chronic secondary neuroinflammation and pro-inflammatory microglial signaling around the spinal lesion
Supplying paracrine neurotrophic signals (including BDNF, GDNF, and VEGF pathways) to support spared neural tracts
Supporting surviving oligodendrocytes and promoting a healthier perilesional tissue microenvironment
Enhancing local microvascular endothelial signaling and cellular metabolic resilience
Providing biological support that complements your ongoing physical and occupational rehabilitation program
Following mechanical compression or contusion, damaged blood vessels and cells trigger an aggressive secondary wave of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), glutamate excitotoxicity, and lipid peroxidation that expands tissue damage into neighboring segments.
Wharton's jelly MSCs and exosomes intervene in this cascade by secreting anti-inflammatory mediators and antioxidant enzymes that neutralize oxidative stress and reprogram pro-inflammatory M1 macrophages and microglia into reparative M2 phenotypes, protecting vulnerable perilesional neurons from secondary cell death.
02
Glial scar signaling & microglial activation around the lesion
Reactive astrocytes and chronically activated microglia form a dense biochemical barrier around the injury site, depositing extracellular matrix molecules that physically and chemically block regenerating axonal sprouts from forming new connections.
Paracrine factors released by WJ-MSCs — particularly hepatocyte growth factor (HGF) and matrix-regulating exosomal microRNAs — help modulate reactive astrocyte signaling and remodel the perilesional extracellular matrix, fostering a more permissive tissue bridge for synaptic reorganization and axonal plasticity.
03
Demyelination & conduction stress in spared neural tracts
Apoptosis of myelin-producing oligodendrocytes leaves anatomically intact axons across the injury zone stripped of their insulating sheath, causing severe signal conduction block and leaving surviving pathways unable to transmit motor or sensory commands.
Intrathecal WJ-MSCs and exosomes deliver BDNF, IGF-1, and oligodendrocyte-supportive microRNAs directly into the cerebrospinal fluid, helping protect surviving oligodendrocytes and encouraging endogenous oligodendrocyte precursor cells to remyelinate spared nerve fibers and restore signal transmission.
04
Impaired neurotrophic & microvascular perfusion support
Microvascular disruption and capillary loss around the spinal lesion starve surviving neurons and glia of oxygen, glucose, and essential neurotrophic growth factors needed to power cellular repair and rehabilitation-induced rewiring.
WJ-MSCs and their exosomes secrete vascular endothelial growth factor (VEGF) and angiopoietins that stimulate new capillary formation and endothelial repair, while simultaneously supplying GDNF and NGF to restore metabolic and trophic support across the recovering spinal network.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Biological rationale
Transforming the perilesional spinal microenvironment to support spared tracts
In most spinal cord injuries, a rim of surviving white-matter nerve fibers persists around the central lesion cavity, yet remains functionally silent due to chronic inflammation, demyelination, and inhibitory chondroitin sulfate proteoglycans in the glial scar. Regenerative medicine focuses on modifying this perilesional tissue environment rather than relying solely on mechanical stabilization. By calming persistent microglial toxicity, restoring microvascular oxygen delivery, and supplying local neurotrophic signals, biological therapy aims to help dormant or demyelinated axons regain conductivity and participate in rehabilitation-driven neuroplasticity.
WJ-MSCs & exosomes
Dual cellular and vesicular signaling for neural and vascular repair
Wharton's jelly-derived MSCs and their purified exosomes provide complementary mechanisms of action within the injured central nervous system. Live WJ-MSCs delivered into the cerebrospinal fluid respond to inflammatory cues by secreting neurotrophic factors (BDNF, GDNF, NGF), anti-scarring hepatocyte growth factor (HGF), and immunomodulatory cytokines that protect stressed neurons and oligodendrocytes. Simultaneously, nanoscale WJ-MSC exosomes penetrate deep into spinal tissue to transfer regulatory microRNAs and protective proteins directly into axons, Schwann-like and glial support cells, and capillary endothelium — supporting remyelination, axonal sprouting, and local microcirculation.
Individualized protocol
Precision planning around your MRI anatomy, injury level, and AIS grade
Every spinal cord injury has a unique anatomical signature defined by cervical, thoracic, or lumbar level, complete or incomplete AIS grade, spinal hardware, and time elapsed since trauma. Our medical team carefully reviews your spinal MRI images, operative notes, and rehabilitation assessments before recommending a protocol. We tailor the exact Wharton's jelly MSC cell dosage, exosome concentration, and combination of intrathecal (with or without sedation), intravenous, and intranasal routes to match your anatomy and set clear, realistic functional objectives.
Our treatment approach & administration routes
Our four-part neurological protocol for spinal cord injury
Based on our medical team's evaluation of your spinal imaging and clinical status, we combine up to four targeted biological administration pathways using GMP-certified Wharton's jelly MSCs and exosomes.
01
Intrathecal WJ-MSC Administration
Performed via lumbar puncture with or without sedation depending on clinical circumstances, intrathecal delivery places fresh, GMP-certified Wharton's jelly-derived MSCs directly into the cerebrospinal fluid circulating around the spinal cord. By bypassing the blood-spinal cord barrier, intrathecal WJ-MSCs bathe the perilesional spinal segments in neurotrophic factors (BDNF, GDNF, NGF, HGF) and anti-inflammatory signals that support spared axons, oligodendrocytes, and synaptic circuits.
Role in your protocolServes as the core spinal delivery route in your protocol, carefully evaluated against your spinal MRI, prior fixation hardware, and canal patency to ensure safe CSF administration.
02
Intravenous WJ-MSC Administration
Systemic intravenous infusion of Wharton's jelly-derived MSCs regulates circulating pro-inflammatory cytokines, shifts systemic monocyte and macrophage populations toward reparative M2 states, and supports microvascular endothelial health throughout the body after spinal trauma.
Role in your protocolProvides systemic immunomodulation and vascular trophic support that complements central intrathecal administration.
03
Intravenous WJ-MSC Exosome Administration
Wharton's jelly MSC-derived exosomes carry a concentrated nanoscale cargo of growth factors, anti-inflammatory proteins, and regulatory microRNAs. Infused intravenously, these vesicles circulate freely through small capillary beds and cross the blood-spinal cord barrier to deliver intracellular repair signals to stressed neurons, glial cells, and vascular endothelium.
Role in your protocolPaired with WJ-MSC infusions to amplify intercellular communication and sustain paracrine repair signaling between cell administrations.
04
Intranasal Exosome Administration
Non-invasive intranasal administration delivers WJ-MSC-derived exosomes across the upper nasal mucosa to engage olfactory and trigeminal neural pathways toward the central nervous system, offering a needle-free route for central neurotrophic and anti-inflammatory signaling.
Role in your protocolIncluded as a non-invasive central adjunct; we note transparently that the exact proportion of intranasally administered exosomes reaching specific human brain and spinal regions remains under study.
What we aim to achieve
How biological repair signaling connects to your recovery goals
Our medical team documents your baseline neurological profile in Istanbul and follows your progress at 1, 3, and 6 months alongside your ongoing rehabilitation program.
01
Spared tract conductivity, motor strength & trunk control
By supplying BDNF, GDNF, and remyelination-supportive signals to anatomically spared fibers around the lesion, the protocol aims to help surviving neural pathways transmit signals more effectively during physical therapy. We document baseline motor scores, trunk stability, and muscle recruitment to track incremental gains over time.
Calming perilesional inflammation and nourishing dorsal sensory tracts aims to support clearer tactile, thermal, or proprioceptive feedback below the level of injury. During follow-up, we track sensory dermatome changes alongside practical improvements in seated balance, transfers, upper-limb endurance, and assisted mobility.
Chronic microglial hyperexcitability in the injured spinal cord often drives severe muscle spasticity and burning neuropathic pain. As WJ-MSCs and exosomes modulate local glial inflammation and cytokine signaling, we monitor patient-reported improvements in muscle tone, nerve comfort, and autonomic stability.
04
Procedure safety & structured 1, 3, and 6-month follow-up
We oversee your immediate recovery after intrathecal and intravenous administration in Istanbul and provide complete GMP cell viability documentation. Our medical team conducts scheduled remote evaluations at 1, 3, and 6 months to review your neurological progress alongside your rehabilitation team.
How treatment is personalized
How our medical team evaluates your spinal cord injury
Contact us with your injury history, spinal MRI reports, and neurological assessments. Uzm. Dr. Cihan Bolat and our medical team review your case to determine clinical suitability, develop an individualized WJ-MSC and exosome protocol, and explain the administration routes, intended therapeutic objectives, and costs before you travel.
Medical history & reports we request
Spinal MRI or CT images and radiological reports showing the injury level and spinal canal
Operative notes from prior spinal stabilization or decompression surgeries, if applicable
Neurological and rehabilitation summaries noting injury level, completeness (AIS grade), and timeline
Current medication list, including any anticoagulants or spasticity medications
Recent routine blood panels and general medical history
Clinical suitability & timing checks
Acute spinal instability or active cord compression requiring urgent neurosurgical intervention
Active systemic infection, untreated pressure ulcer infection, or urinary tract infection
Anatomical blockage or lumbar hardware that contraindicates safe intrathecal lumbar puncture (where IV/intranasal routes may be evaluated instead)
Uncontrolled respiratory or hemodynamic instability that makes international travel unsafe
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Spinal cord injury treatment cost in Istanbul
Following your free medical evaluation, we provide a transparent written treatment plan detailing the proposed Wharton's jelly MSC and exosome dosages, intrathecal, intravenous, and intranasal administration routes, hospital monitoring, and full travel logistics in Istanbul.
Our 2026 MSC and exosome program planning range starts from $7,000–$18,000 depending on cell dosage, exosome concentration, and selected administration routes, confirmed after your free medical review.
Individualized Wharton's jelly MSC cell count and exosome concentration
Combination of intrathecal (with or without sedation), intravenous, and intranasal administration routes
Number of administration days, hospital procedure suite support, and clinical observation
GMP laboratory quality certificates, accessible airport/hotel transfers, and 1, 3, and 6-month follow-up
Which combination of intrathecal WJ-MSCs, intravenous WJ-MSCs, and exosomes is appropriate for my injury level and spinal anatomy?
02
Whether intrathecal administration will be performed with or without sedation and how my prior spinal hardware is accounted for.
03
What realistic therapeutic objectives the protocol aims to support alongside my ongoing physical rehabilitation.
04
The exact itemized cost of my protocol, accessible transport arrangements, and expected stay duration in Istanbul.
Evidence & important considerations
Clinical evidence and important scientific context
Clinical research in spinal cord injury spans both intrathecal mesenchymal stromal cell infusions and experimental neurosurgical cell implants. We review each study transparently so patients understand how non-surgical Wharton's jelly MSC and exosome protocols differ from surgical trials, and why outcomes vary by injury completeness and timing.
Human embryonic stem-cell-derived oligodendrocyte progenitors
Study design
Open-label study, 25 adults with subacute cervical SCI
Finding
Reported early surgical feasibility and safety observations with exploratory upper-extremity motor follow-up in subacute cervical injuries.
Limitation
Tested an invasive neurosurgical intraspinal implant in subacute patients rather than our clinic's non-surgical intrathecal and intravenous WJ-MSC protocols.
Intrathecal Wharton's jelly MSC administration was well tolerated with individual sensory observations, though group-level motor changes did not separate from placebo over short follow-up.
Limitation
Small sample size in chronic SCI highlights that clinical responses vary between individuals and cannot guarantee motor restoration.
Frequently asked questions about spinal cord injury
We do not perform open spinal neurosurgery. Depending on your spinal MRI and individualized protocol, we combine intrathecal Wharton's jelly MSC administration into the cerebrospinal fluid (with or without sedation), intravenous WJ-MSC infusion, intravenous WJ-MSC exosomes, and intranasal exosomes.
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.
